NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn ...

Notable profits for the buyer who lifted the $0.25 offer for 9,851 Cassava Sciences (SAVA) Feb-25 3 calls yesterday at 10:51ET when underlying ...

Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $2.36 which represents a decrease of $-0.04 or -1.67% from the prior close of $2.4. The stock opened at $2.36 and touched a low of $2 ...

A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined 83.9% over the past four weeks. However, given the fact that it is now in ...

Specifically, Defendants misrepresented and/or failed to disclose that: (1) Cassava’s drug, simufilam, was not capable of abating the progression of Alzheimer’s Disease, even in mild to ...

Cassava Sciences Inc (SAVA) stock saw a modest uptick, ending the day at $2.41 which represents a slight increase of $0.06 or 2.55% from the prior close of $2.35. The stock opened at $2.34 and touched ...

Robbins LLP reminds investors that a class action was filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for wrongdoing between February 7, 2024 ...

BNP Paribas Financial Markets grew its stake in Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report) by 150.1% during the third ...

THE LAWSUIT: A class action securities lawsuit was filed against Cassava Sciences, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAVA Stockholders Have Opportunity to Lead Cassava Sciences, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!